G1 Therapeutics to Participate in the Cowen 43rd Annual
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Stay updated with breaking news from Jack Bailey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
The bill would increase sanctions for indecent exposure to a minor, including imprisonment of up to five years and a fine of up to $10,000, or both.
G1 Therapeutics Inc said on Monday it would terminate a late-stage study of its lead drug as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer, sending... | February 13, 2023
Maryland legislation would increase sanctions for those who intentionally expose themselves to a minor.